<DOC>
	<DOC>NCT02351232</DOC>
	<brief_summary>A randomized placebo-controlled clinical trial investigating the effects of Liraglutide as an add-on to intensive insulin therapy in overweight insulin pump treated type 1 diabetes patients in suboptimal glycemic control.</brief_summary>
	<brief_title>The Lira Pump Trial</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 1 diabetes ≥ 1 year BMI &gt; 25 kg/m2 Insulin pump ≥ 1 year HbA1c &gt; 58 mmol/mol Use of carbohydrate counting and the insulin pump bolus calculator Gastroparesis Impaired renal function (eGFR &lt; 60 ml/min/1.73m2) Liver disease with ALAT &gt; 2.5 times the upper limit of the reference interval Acute or chronic pancreatitis or history of chronic pancreatitis or idiopathic acute pancreatitis Inflammatory bowel disease History of cancer (except basal cell skin cancer) which in the investigators opinion could interfere with the results of the trial, or cancer during the past 5 years Thyroid adenoma Subjects with personal or family history of MTC or MEN2 Use of antidiabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start Known or suspected alcohol or drug abuse Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation Females of childbearing potential who are pregnant, breastfeeding or intend to become pregnant or are not using adequate contraceptive methods. Simultaneous participation in any other clinical intervention trial Known or suspected hypersensitivity to Liraglutide Inability to understand the patient information and to give informed consent Acute treatment required proliferative retinopathy or maculopathy (macular oedema) Any Cardiac disorder which in the investigators opinion could interfere with the safety and results of the trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>